Upload
vaska-tone
View
550
Download
2
Tags:
Embed Size (px)
Citation preview
The EMA Inspection ProcessProcedures, Timelines & Expectations
Presented byVaska Toné
TYPES OF INSPECTIONS
EMA DEFINITIONS & PROCEDURES
EMA INSPECTION TIMELINES
EMA INSPECTION PREPARATION
DOSSIER REQUEST
SITE SELECTION
INSPECTION SELECTION
INSPECTION PROCESSES
GCP Inspections
2
GCP Inspections
Systems Inspections● Look at all relevant SYSTEMS for CTIMPs
o CTIMP = Clinical Trial of Investigational Medicinal Product
● Check that the expected process is used in practice
Study Specific Inspections● Carefully review the study data● Is it real, reliable and trustworthy?● Reduced reliance on interviews● But site staff will/may be interviewed
3
Inspection Reason
Mainly based on questions raised by assessors reviewing the submitted dossier
But can be caused by intelligence obtained relating to potential problems within clinical trials
EMA has no inspectors – they “subcontract” inspecting to the individual member states to perform the inspection according to the EMA SOPs
Each member state has its own inspectorate and inspects in its own territory independently
4
EMA Definitions
Reporting Inspectorate (RI)● The inspectorate member state designated by the EMA to
manage the inspection and timelines and writing the Integrated Inspection Report
Reporting Inspector● The Inspector at the RI with responsibility for the inspection
Lead Inspector (LI)● The inspector leading the conduct of an inspection and writing
the Inspection Report. The LI is based in the member state where the inspection is performed
5
EMA Definitions
Inspection Report (IR)● The report produced after each site inspection by the Lead
Inspector. Should responses not be provided in the expected timeframe this fact is documented in the report by the LI.
Integrated Inspection Report (IIR)● Prepared by the RI based on each of the IRs for the whole
inspection. Contains an evaulation of the quality of the data and GCP compliance. Signed by all LIs who have written IRs for the overall inspection. Includes recommendations for follow-up and further inspections
6
EMA Inspections
EMA has no inspectors – they “subcontract” inspecting to the individual EU member states to perform the inspection according to the EMA SOPs
Each member state has its own inspectorate and inspects in its own territory independently
All EMA procedures are documented and in the public domain
7
EMA Procedures
All EMA procedures are documented and in the public domain
Located on the EMA website under:o EMA Home Regulatory → Human Medicines → Inspections →
GCP Compliance → Inspections Procedure
http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/document_listing/document_listing_000140.jsp&mid=WC0b01ac05800296c6
This documents all the EMA SOPs relating to GCP inspection processes
Each SOP can be opened and is readable
8
EMA Procedures9
EMA Procedures10
EMA Timelines11
Dossier
Dossier request – usually 30 days prior to inspection• Can be very helpful to get to know your own company better and for
QA to be “In the Loop”• Takes a long time to complete with participation of many
departments• Listing of systems in use for the trials and those outsourced• List of trials taken place over a period of years• Plan – inspector prepares with input from the inspectee• Studies are pre-selected by the inspectors• Generally more than one study selected
12
Dossier
Dossier Details: There are 2 sections that need to be completed:
• Section 1 has 6 required items to be provided:• Item 1: Organizational Charts• Item 2: List of Clinical Trial Processes (SOPs, etc)• Item 3: Adverse Event Reporting Systems & Procedures• Item 4: List of Computer Systems & Validation Status• Item 5: For non-commercial organizations only• Item 6: List of clinical trials (use the provided spreadsheet)
13
Dossier
Section 2 has 3 items:• Item 1 & 2: Names and addresses of all facilities involved in the
clinical trials, including:o Vendors (i.e. labs, drug depots) o CROs (full scope, niche i.e.: DM, Stats, Safety)o Support services (readers: ECG, CT/MRI/Bone
Scan imaging, etc)
14
Dossier
Section 2 has 3 items:• Item 3: Summary information of your organization’s clinical trial
systems (info on 1 side of paper for each department)
1. Contract and Agreement Preparation
2. Quality System (including training)
3. Clinical Quality Assurance
4. Project Management
5. Clinical Trial Monitoring
6. Pharmacovigilance (including medical expertise)
7. Regulatory Affairs
8. Computer Systems
15
Dossier
Item 3 continued: 9. Investigational Medicinal Products (IMP)
10. Data Management & Statistics
11. Clinical Trial Reporting
12. Trial Master File
13. Archiving
14. Clinical Facilities
15. Laboratories
16. Equipment Maintenance
16
Investigator Site Selection
EMA• Can be selected by the EMA or the assessors of the
data depending on the information and intelligence held about each investigator site
• The inspectors may add in more or change the investigator sites after review of the data
17
Inspection Process
• Usually site inspection AFTER the Sponsor/CRO inspection but NOT always
• If the Inspection is based on a marketing application, more emphasis will be placed on data credibility and assurance that data exists and is true at the site
• Less interview, more data review• CRA should be present to provide assistance to the
inspectors• Documents may be requested during the inspection
(requested using a request form)
18
Inspection Topics
System inspections• Look at any issues seen in monitoring visit reports• Issues with safety, data or site knowledge of GCP or the protocol• Not always the highest recruiter
Study Inspections• Depends on the issues that the assessor has noted within the
submitted dossier• It may be an issue relating to credibility of site data• It may be a company data management issue• The investigator site provides the data so are key inspection
areas for both types of inspection
19
Inspector Selection
• Two member states present if EMA requested, the host member state plus one other member state
• The lead inspector will contact the site to arrange the dates for the inspection
• But the dates need to be acceptable to both member states attending the inspection
20
General Inspection Process
• Review of documentation and interview with staff members
• Interviews can be by video/telecon if necessary• Documents will be requested using a request form• Further unannounced studies can be requested• Review of areas where the research is managed• Inspectors can go “off-plan” if there is a need
21
On Site Inspection Conduct
• Inspection hours – from 9am to 5pm but can be longer if necessary
• Opening meeting – to explain the purpose of the inspection
• Inspected company provides a SHORT relevant presentation to the inspectors
• Have ALL requested documentation ready from the beginning
22
Expectations & Close Out
• Document review sessions – leave the inspectors alone unless they request assistance
• Don’t offer more info than necessary – if TMF is paper leave it at that, if you have online access to it, the inspector will want the same
• Inspectors closed meeting to collate findings and prepare for closing
• Closing meetingo to provide the observations noted and the grading of
those observationso to inform inspectee of the selected investigator sites
23
Any Questions?24
LaVaPharm Consulting25
Vaska TonePresident & CEOLaVaPharm Consulting LLC
Email: [email protected]
US Office Phone: +1-951-240-5635
European Office: +389-75-417-417